bluebird bio's Rare Blood Disorder Drug Tagged a Breakthrough by the FDA

February 2, 2015 By Krystle Vermes , BioSpace.com Breaking News Staff Gene therapy developer bluebird bio , announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to LentiGlobin, its drug product for the treatment of transfusion-dependent patients with beta-thalassemia major. The LentiGlobin BB305 Drug Product is also aimed at treating severe sickle cell disease by inserting a human beta-globin gene into the patient's own hematopoietic stem cells ex vivo.

http://ift.tt/1z63dAF